TGM2 and myelodysplastic syndrome: Finally, our study showed the upregulation of TGM2 in both MDS risk groups, highlighting both its relevance to MDS pathogenesis by dysregulating autophagy and apoptosis and its potential role as a therapeutic target [27], as we previously reported [12].